We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





Integrated LC-MS System to Be Released in Conjunction with AACC Annual Meeting

By LabMedica International staff writers
Posted on 01 Aug 2016
Print article
Image: The CLAM-2000 automated LC-MS sample preparation system (Photo courtesy of Shimadzu Scientific Instruments).
Image: The CLAM-2000 automated LC-MS sample preparation system (Photo courtesy of Shimadzu Scientific Instruments).
What may be the first truly integrated sample preparation system for LC-MS (liquid chromatography-mass spectrometry) that allows users to process samples in an instrument that is directly attached to the LC-MS system is to be released at the 2016 AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA).

Shimadzu Scientific Instruments (Kyoto, Japan) had announced that the release of the Clinical Laboratory Automation Module-2000 (CLAM-2000), a fully integrated sample pretreatment module for LC-MS, will coincide with the 2016 AACC Annual Meeting.

The CLAM-2000 system, which is on display in Booth 4054 of the expo, automatically performs all the processes necessary for analyzing blood and other biological samples, from scanning in information from the blood collection tubes to sample pretreatment and LC-MS analysis. The for-research-use-only instrument is the first truly integrated sample preparation system for LC-MS. It allows users to process samples in an instrument that is directly attached to the LC-MS system, a simple and safe way for lab personnel to process and analyze samples.

The instrument is controlled by a user-friendly interface that offers a variety of functions that regulate reagent management, calibration curve management, control management, and system maintenance management. By automating operations such as dispensing, stirring, filtering, heating, and sample transfer, the system effectively improves data accuracy and achieves the high level of reproducibility needed for clinical research.

“This system highlights the considerable progress made in the use of mass spectrometers for high-sensitivity detection in medical R&D,” said Dr. Scott Kuzdzal, general manager of marketing at Shimadzu Scientific Instruments. “It is ideal for medical research centers, university medical departments, hospital pharmaceutical departments, and contract research organizations that are dealing with issues of variability in analytical results or laboratory efficiency. It can also effectively support forensic applications conducted by universities, research institutes, and testing companies.”

Related Links:
AACC Annual Meeting & Clinical Lab Expo
Shimadzu Scientific Instruments
New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Dengue Virus Test
LINEAR Dengue-CHIK

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.